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Abstract
The metabolism of S-adenosylmethionine (AdoMet), a key molecule in regulating T cell differentiation and proliferation,
is different in normal and leukemic T cells. To delineate the basis for these differences we studied the transcriptional
regulation of human methionine adenosyltransferase II (MAT II), which catalyzes AdoMet synthesis in these cells. Recently,
we identified an Sp1 site in the proximal promoter of the MAT2A gene, which encodes the K2 catalytic subunit of MAT II,
that is essential for the in vitro and in vivo promoter activity in Jurkat leukemic T cells, and that involves binding of the
nuclear factors Sp2 and Sp3, but not Sp1. Here, the in vitro and in vivo activity of the proximal MAT2A promoter in normal
resting, PHA-stimulated, and leukemic human T cells was compared. Significantly different patterns of protein factor
interaction in the proximal region of the MAT2A promoter were found. Normal resting and activated T cells produced
complexes of significantly lower molecular weight than those formed in leukemic T cells. Supershift studies coupled with
analysis of proteins bound to the proximal promoter suggest that low levels of expression of Sp2 and Sp3 in normal T cells
may be responsible for the difference in the in vitro promoter activity between normal and leukemic cells. Mutation of the
key Sp1 site equally reduced the in vivo promoter activity in normal and malignant T cells ; by contrast, it had significantly
different effects on protein^DNA interactions in normal and leukemic T cells. Together, the data support the idea that
differences in protein^DNA interactions may contribute to significant differences in MAT2A regulation in normal and
malignant cells. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
S-Adenosylmethionine (AdoMet), a pivotal bio-
logical molecule, serves as the major donor of methyl
groups in transmethylation reactions and can be de-
carboxylated to become a precursor in the polyamine
biosynthetic pathway [1,2]. In addition, AdoMet is a
cofactor and a regulator of important metabolic
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pathways [2]. AdoMet is synthesized by the enzyme
methionine adenosyltransferase (MAT, EC 2.5.1.6
[3,4]). Studies have shown that intracellular AdoMet
levels vary considerably in di¡erent tissues and in
di¡erent stages of development and di¡erentiation
of the same tissue [5^9]. Although the size of the
AdoMet pool is controlled by di¡erences between
synthesis and utilization, regulation of AdoMet levels
appears to be primarily at the level of its synthesis by
MAT. A key to understanding the control of Ado-
Met synthesis in di¡erent tissues, di¡erent stages of
cell growth, and in malignant transformation lies in
understanding the control of MAT expression. Most
organisms carry two genes that encode the catalytic
K subunit of di¡erent MAT isozymes [10]. In hu-
mans, two MAT isozymes exist: MAT I/III and
MAT II [10]. MAT I and MAT III represent a
homotetramer and a homodimer of the K1 subunit,
which is encoded by the MAT1A gene and which is
expressed only in the liver. MAT II on the other
hand is widely expressed in all tissues and has a
more complicated subunit structure that includes
two K2 catalytic subunits, one of which is modi¢ed
(K2P), and an unrelated L subunit of unknown stoi-
chiometry (K2/K2P)n(L)n [11].
The catalytic K2 subunit is encoded by the
MAT2A gene, located on chromosome 2p1.1 [12],
whereas the regulatory L subunit is encoded by the
MAT2B gene, located on chromosome 5q34-35-1
[12^14]. The association of the L subunit with the
catalytic K2 subunits a¡ects the overall kinetic prop-
erties of the holoenzyme by rendering it more sensi-
tive to feedback inhibition by AdoMet [13,15,16].
MAT II was ¢rst puri¢ed to homogeneity from hu-
man leukemic cells and has been studied in a variety
of tissues including kidney, brain, lens, erythrocytes,
and lymphocytes [6,17^21].
Many studies have documented changes in MAT
activity, isozyme expression, and AdoMet levels as a
consequence of malignant transformation [21^25].
We have been particularly interested in MAT II reg-
ulation in human lymphocytes inasmuch as our pre-
vious studies have shown signi¢cant di¡erences in
AdoMet levels and fractional turnover in normal
and leukemic T cells [5,22]. Phytohemagglutinin
(PHA) induces proliferation and stimulates MAT ac-
tivity in peripheral blood mononuclear cells (PBMC),
as well as an increase in intercellular AdoMet con-
centrations [5,22]. MAT2A mRNA synthesis reaches
a maximum rate within 4^8 h after stimulation in
these cells [16]. Superantigen stimulation of T cells
via the T cell receptor (TCR) induces a similar in-
crease in the expression of K2/K2P subunits but
causes a marked downregulation of the regulatory
L subunit. By contrast, expression of all MAT II
subunits is constitutively elevated in leukemic T cells,
and PHA stimulation of these cells does not elicit
any further increase in MAT II expression, AdoMet
levels, or turnover [5,16,22].
Together, these observations suggested potentially
signi¢cant di¡erences in MAT II regulation in nor-
mal and leukemic T cells. To test the hypothesis and
unravel the mechanisms involved in regulating K2/
K2P expression in activated and transformed T cells,
we recently cloned and characterized the MAT2A
promoter and analyzed its activity in Cos-1 cells
and Jurkat leukemic T cells [27]. Promoter sequences
contained between 387 and 358 from the transcrip-
tion start site were found to harbor important ele-
ments required to drive transcription of the MAT2A
gene, and a speci¢c Sp1 site located at position 369
was found to be essential for promoter activity in
Cos-1 cells and Jurkat leukemic T cells. In this study,
we compared the in vivo and in vitro activity of the
proximal MAT2A promoter in normal resting, acti-
vated, and leukemic T cells. We report signi¢cant
di¡erences in protein factor interactions with the
MAT2A promoter in resting, activated, and leukemic
T cells. These di¡erences may shed light on the
mechanism of di¡erential regulation of these sub-
units in normal and malignant cells.
2. Materials and methods
2.1. Leukemic and normal human T cells
Freshly isolated acute lymphoblastic leukemia
(ALL)-2 cells (T cells, Mid Thymocyte) from pedia-
tric patients were provided by Dr. F. Behm at St.
Jude Children’s Research Hospital. The Jurkat T
cell line was from the American Type Tissue Culture
Collection (Rockville, MD). Heparinized blood was
obtained from normal adult volunteers and the
PBMC were isolated using Ficoll-Hypaque density
gradient centrifugation as previously described [16].
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T cells were isolated from PBMC by E-rosetting as
detailed elsewhere [26]. All cells were cultured in
RPMI medium supplemented with 10% heat inacti-
vated fetal bovine serum, 2 mM L-glutamine, 50 Wg/
ml of streptomycin, and 50 U/ml of penicillin (re-
ferred to as RPMI complete).
For stimulation of normal T cells, 1^2U106 cells/
ml were stimulated with 2 Wg/ml PHA (Boehringer
Mannheim) and cultured in RPMI complete at 37‡C,
95% humidity and 5% CO2. At speci¢c times after
the initiation of culture, the cells were harvested and
used for preparation of nuclear extract.
2.2. In vitro analysis of the MAT2A promoter activity
by electrophoretic mobility shift (EMSA) and
supershift assays
Double-stranded oligonucleotide probes copying
speci¢c regions of the proximal MAT2A promoter
were generated by PCR ampli¢cation with 32P-end-
labeled primers listed in Figure 1. Nuclear extracts
from ALL-2, Jurkat, normal resting or PHA-stimu-
lated T cells were prepared by washing cell pellets in
1UHPBS, resuspending in a hypotonic bu¡er (10
mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
0.2 mM PMSF, and 0.5 mM DTT). After centrifu-
gation for 5 min at 3000 rpm, the pellet was resus-
pended in the same bu¡er and allowed to swell on ice
for 10 min, then homogenized. Nuclei were harvested
by spinning for 15 min at 4000 rpm, resuspended in
hypotonic bu¡er and homogenized. An equal volume
of high salt bu¡er (20 mM HEPES, pH 7.9, 25%
glycerol, 1.5 mM MgCl2, 1.2 M KCl, 0.2 mM
EDTA, 0.2 mM PMSF, and 0.5 mM DTT) was
added, and the extracted nuclei were centrifuged
for 30 min at 14 500 rpm at 4‡C. Supernatants
were dialyzed for 1 h against 2 l of dialysis bu¡er
(20 mM HEPES, pH 7.9, 20% glycerol, 100 mM
KCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM
DTT). Aliquots were stored at 380‡C.
Binding reactions were performed in 20 Wl ¢nal
volume by incubating 60 fmol (approx. 50 000 cpm)
of 32P-labeled probe with 5 Wg of crude nuclear ex-
tracts from the various types of T cells in the pres-
ence of 2 Wg of poly(dI-dC), 1 Wg salmon sperm
DNA in 20 mM HEPES, pH 7.9, 50 mM KCl,
1 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 10%
glycerol and 6 Wg BSA for 40 min on ice. The reac-
tions were conducted in the absence or presence of
speci¢c or non-speci¢c competitors, both added at
100-fold molar excess. Speci¢c competitors were
cold probes; non-speci¢c competitors were unlabeled
PCR ampli¢cation products of an unrelated DNA
sequence, free of sites of interest, and similar in
size to speci¢c competitor. The DNA^protein com-
plexes formed were analyzed by electrophoresis on
non-denaturing 4% polyacrylamide gels as detailed
elsewhere [27].
Supershift assays were performed using antibodies
(Abs) to speci¢c factors that have corresponding rec-
ognition elements within the MAT2A promoter re-
gion analyzed. Binding reactions were carried out as
described above in the absence or in the presence of
2 Wg Ab speci¢c to one of the transcription factors of
interest. The Ab was either premixed with the nu-
clear extract, incubated for 30 min at room temper-
ature prior to addition of radiolabeled probe, or
added after the binding reaction was completed and
incubated for 30 min on ice. The following Abs (San-
ta Cruz Biotechnology, Santa Cruz, CA) were used
in supershift analyses: mouse anti-Sp1 mAb (cat.
No. sc-420X), anti-Sp2 (cat. No. sc-643X), anti-Sp3
(cat. No. sc-644X), anti-Sp4 (cat. No. sc-645X), anti-
PEA3 mAb (cat. No. sc-113X), rabbit polyclonal
anti-AP-2 (cat. No. sc-184X), anti-cMyb (cat. No.
sc-7874X) Abs, and goat polyclonal anti-GATA1
(cat. No. sc-1233X).
2.3. Generation of luciferase reporter wild type and
mutated constructs of the MAT2A promoter
A series of MAT2A promoter deletion constructs
were generated and cloned upstream from a ¢re£y
luciferase (LUC) reporter gene in the pGL3-En-
hancer vector (Promega) as previously described
[27]. The proximal MAT2A promoter three Sp1 sites
located at 314 (Sp1-1 site), 347 (Sp1-2 site), and
369 (Sp1-3 site). Constructs with individually mu-
tated Sp1 sites were generated by site-directed muta-
genesis as detailed elsewhere [27] and cloned into the
pGL3-Enhancer vector (Promega).
2.4. In vivo analysis of the MAT2A promoter activity
Functional expression of deletion constructs of the
proximal MAT2A promoter was analyzed as previ-
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ously described [27], with important modi¢cations
introduced to optimize the transfection of normal
T cells.
Transfection of normal T cells with the pGL3-
MAT2A constructs was achieved by the method of
Keller et al. [28] with the following modi¢cations.
T cells (2.5U105) were seeded into 12-well tissue cul-
ture plates that had been coated with an adherent
monolayer of Cos-1 cells at approx. 50% con£uence.
The cells were co-cultured overnight to allow the
T cells to adhere to the Cos-1 cell monolayer. The next
day, the wells were gently rinsed twice with Hanks’
balanced salt solution (HBSS), and then the pGL3-
MAT2A promoter deletion constructs (1.25 Wg) were
added to each well along with the control Renilla
luciferase vector pRL-CMV DNA (40:1 ratio) in a
¢nal volume of 400 Wl serum-free DMEM^RPMI
medium (1:1) containing 7.7 Wl TransIT-LT1 (Mi-
rus). After incubation at 37‡C for 2 h, 2 ml of com-
plete DMEM^RPMI (1:1) medium plus 10% FCS
were added and incubated overnight. The following
day, six wells received PHA (2 Wg/ml ¢nal concen-
tration) and six wells received medium alone (unstim-
ulated T cells). Cells were harvested 6 h later. The
adherent cells were washed with 1UHBSS and then
recovered by trypsinization for 5 min followed by the
addition of serum-containing medium to inhibit tryp-
sin activity. The cell mixture was incubated for 2 h in
plastic tissue culture plates to separate the adherent
Cos-1 cells from the non-adherent T cells. The Cos-1
cells adhered readily and the non-adherent T cells
were recovered by gentle pipeting. T cells isolated
in this fashion were subjected to two additional
cycles of plastic adherence to remove any residual
Cos-1 cells.
Transfection of Jurkat cells with the pGL3-
MAT2A constructs was achieved using a similar
method with the modi¢cations detailed in Halim et
al. [27]. The purity of the recovered Jurkat cells was
s 93% as analyzed by £ow cytometry using a PerCP-
Cy5.5-labeled monoclonal anti-human CD3 antibody
(Beckton and Dickinson, clone SK7).
2.5. Western blot analysis of Sp3 in normal and
leukemic T cells
Nuclear proteins from Jurkat cells, ALL-2 T cells,
normal resting T cells or from T cells that had been
stimulated with PHA for 6 h were prepared as pre-
viously described [27], and loaded onto 10% SDS^
PAGE gels, followed by immunoblotting as de-
scribed previously [13] using an antibody to the tran-
scription factor Sp3 (Santa Cruz No. sc-644X) as
detailed elsewhere [27]. In some experiments, the pro-
tein was ¢rst puri¢ed on a probe D (376/354) DNA
a⁄nity column prior to Western blot analysis.
Oligonucleotides representing the forward and re-
verse strands of probe D (376/354) were synthesized
with the additional ACGT or TGCA at the 5P end of
the appropriate strand to allow probe oligomeriza-
tion of the double-stranded probe, and to facilitate
coupling to the cyanogen bromide (CNBr) beads
(Pharmacia). The forward and reverse oligonucleo-
tides were annealed, ligated and added to pre-swollen
CNBr-activated Sepharose beads and incubated for
20 h at room temperature on a vertical rotator in the
presence of 100 mM potassium phosphate bu¡er (pH
8.0). The beads were settled, the supernatant was
replaced with 1 M ethanolamine (pH 8.0) and the
mixture was incubated for an additional 3 h at
room temperature on the rotator. The beads were
then subjected to a series of washes, ¢rst with 1 M
ethanolamine (pH 8.0), followed by 10 mM KPO4
(pH 8.0), then by a solution of 1 M KCl containing
1 mM EDTA (pH 7.6), and ¢nally by a solution of
300 mM NaCl, 10 mM Tris^HCl (pH 7.6), 1 mM
EDTA with 0.04% w/v NaN3. The nuclear proteins
were added to the DNA-Sepharose beads in the same
ratio and using the same conditions used for the
EMSA binding reaction described above. The beads
were washed extensively in 1Ubu¡er used for bind-
ing reaction, then eluted in 1USDS^PAGE loading
bu¡er. The eluted proteins were separated on 10%
SDS^PAGE and visualized with silver staining.
Western blots of the a⁄nity puri¢ed DNA-bound
proteins was performed as described above.
2.6. Statistical analysis
Paired t-tests were used to test for signi¢cant dif-
ferences between the in vivo activity of the MAT2A
promoter constructs. All constructs were analyzed in
triplicate, and experiments were performed at least
four times.
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3. Results
3.1. Distinct pattern of protein^DNA complex
formation between MAT2A DNA probes and
extracts from normal and malignant T cells
Our recent studies have determined that the region
between 3163 and +5 of the MAT2A promoter con-
tained the majority of activity required for MAT2A
gene expression. To shed light on the di¡erential reg-
ulation of the MAT2A gene in normal and leukemic
T cells, we examined the in vivo MAT2A promoter
activity in these cells. A series of probes representing
di¡erent segments of the proximal region of the
MAT2A promoter (3163/+5) were generated (Fig.
1) and used in EMSA and supershift assays with
nuclear proteins from normal and leukemic T cells.
Probe A, corresponding to nucleotides 3163/+5 of
the MAT2A promoter (Fig. 1), formed three major
protein^DNA complexes in extracts from Jurkat and
ALL cells (complexes I, II, III; Fig. 2A). Two addi-
tional complexes ^ complex IV and complex V ^
were readily seen in the ALL extracts and to a
much lesser extent in Jurkat cell extracts (Fig. 2A).
Thus the pattern of protein^DNA complex forma-
tion was essentially the same in the established and
freshly explanted leukemic T cells.
By contrast, signi¢cantly lower complexes were
seen with nuclear extracts from normal T cells, and
PHA stimulation was not su⁄cient to induce the
formation of the large size complexes seen with nu-
clear extracts from leukemic T cells (Fig. 2). Com-
plexes IV and V that were seen in ALL cells were
predominant in normal resting and PHA-stimulated
T cell extracts, whereas complexes I, II, and III were
not formed at all (Fig. 2A). An additional complex ^
complex VI ^ was formed transiently in PHA-stimu-
lated T cells after 6 h of stimulation but disappeared
by 8 h (Fig. 2A, lanes S6 and S8, respectively). A
number of small, ill-de¢ned complexes ^ designated
VII and VIII ^ were also present only in extracts
from T cells incubated with probe A (Fig. 2A). An
identical EMSA pro¢le was observed when a smaller
probe, probe B (3110/+5), was used (Fig. 2B).
Probe C (3110/345) and probe D (376/354),
which contain an Sp1 site at position 369 (desig-
nated Sp1-3 site) that has been previously shown to
contain the minimal MAT2A promoter in Cos-1 and
Jurkat cells [27], formed fewer protein^DNA com-
plexes than did probes A and B in both Jurkat and
ALL cells and complex VIII was more de¢ned (Fig.
2C,D). Complex I seemed to co-migrate with com-
plex II in Jurkat and ALL cell extracts, and complex
IV was markedly reduced in ALL and normal T cell
extracts, whereas the pro¢le of complex V remained
the same (Fig. 2C,D). However, when probe D was
used, complex VI appeared in extracts from PHA-
stimulated cells as early as 4 h and persisted through
the 6 h time point (Fig. 2D). Similar to what was
seen with probes A and B, complex VI disappeared
by 8 h following PHA stimulation (Fig. 2D). A new
complex ^ complex IX ^ appeared in extracts from
the 8 h PHA-stimulated normal T lymphocytes when
probes C and D were used (Fig. 2C,D).
3.2. Supershift assay implicates Sp2 and Sp3 in
protein^DNA complexes formed in normal
and leukemic T cells
Probes A and B harbor three Sp1 sites located at
positions 314, 347, and 369 and designated Sp1-1,
Sp1-2, and Sp1-3, respectively. In this study, adding
an antibody to the transcription factor Sp1 caused a
signi¢cant supershift in extracts from both normal
and leukemic T cell with probes A and B (Fig.
2A). This supershift appeared to be slightly dimin-
ished in normal T cells that had been stimulated with
PHA for 8 h (Fig. 2A,B, lane S8). However, none of
the complexes formed between probes C or D and
Fig. 1. Sequence of the proximal MAT2A promoter and probes
used for EMSA and supershift analyses. The functional region
of the proximal MAT2A promoter is depicted with various
transcription factor-binding sites underlined. TSS, transcription
start site. Probes designated A^D were used for EMSA and
supershift analyses.
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the various extracts was supershifted by adding the
Sp1 antibody (Fig. 2C,D). This result is consistent
with our previous observation that all three Sp1 sites
must be on the same DNA fragment for supershift to
occur with the anti-Sp1 antibody [27].
When probe D that contains site Sp1-3 alone
(376/354, Fig. 1) was used, anti-Sp2, -Sp3, and -
Sp4 antibodies caused supershift with extracts from
leukemic T cells but not from normal resting or ac-
tivated T cells (Fig. 3). The anti-Sp2 antibody in-
duced a strong supershift with nuclear extracts
from both the Jurkat and ALL cells (Fig. 3). In the
presence of the anti-Sp3 antibody, complexes I and
III disappeared ^ complex III was either inhibited or
shifted to co-migrate with complex II (Fig. 3). Super-
shift with the anti-Sp4 antibody was considerably
less than with either anti-Sp2 or anti-Sp3 antibodies.
Although the data suggest that Sp2 and Sp3 pro-
teins are involved in complex formation in leukemic
T cells only, failure to demonstrate supershift by
these antibodies with nuclear extracts from normal
T cells may be attributed to low levels of these pro-
teins in normal resting or activated T cells. To ad-
dress this possibility, we analyzed using Western
blots the level of expression of the Sp3 protein in
nuclear extracts from Jurkat, ALL, resting and 6 h
Fig. 2. In vitro analysis of the MAT2A promoter by EMSA shows signi¢cant di¡erences in patterns of protein^DNA interaction with
extracts from normal and leukemic T cells. Probes A, B, C and D described in Fig. 1 were incubated with nuclear extracts from Jur-
kat cells (J), ALL-2 T cells (A), normal resting T cells (R) or T cells stimulated with PHA for 2 h (S2), 4 h (S4), 6 h (S6), and 8 h
(S8). Complexes are designated I to IX in order of mobility, and SS refers to the supershift with an anti-Sp1 antibody. Panels A^D
are autoradiograms of EMSA and supershift analysis using probe A^D, respectively. The probes were incubated without (3) or with
(+) an Sp1 monoclonal antibody. Lane P in each autoradiogram is probe alone. The complexes were analyzed by PAGE as detailed
in Section 2. A novel complex that appears in normal T cells 8 h after PHA stimulation is designated IX in panels C and D, lanes
S8.
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activated T cells. As shown in Fig. 4A, the Sp3 pro-
tein was readily detected in leukemic T cell extracts,
but not in extracts from normal resting or PHA-
stimulated T cells (Fig. 4A). Further, the same results
were obtained when, prior to Western blot analysis,
the nuclear proteins were a⁄nity puri¢ed on a probe
D DNA a⁄nity column (Fig. 4B).
3.3. E¡ect of mutation of the Sp1 sites located in the
proximal MAT2A promoter on the pattern of
protein^DNA interaction in normal and
leukemic T cells
All three Sp1 recognition sites present within
probe B were individually mutated and probes har-
boring the various mutations were used in EMSA
assays to determine if there is a di¡erence between
normal and leukemic T cells. The mutated probes
were used to examine complex formation in extracts
from ALL cells, resting normal T cells, and 6 h
PHA-stimulated normal T cells.
Mutation of sites Sp1-1 and Sp1-2 (probe B:Sp1-
1M, and probe B:Sp1-2M, Fig. 5) reduced the for-
mation of complex V in the ALL cell extracts and
abolished it in normal resting or activated T cell ex-
tracts. However, mutation of the Sp1-1 or the Sp1-2
sites had no e¡ect on supershift with the anti-Sp1
antibody in all nuclear extracts examined (Fig. 5).
Fig. 3. Pattern of supershift with antibodies to di¡erent members of the Sp1 family of transcription factors shows signi¢cant di¡eren-
ces between normal and leukemic T cells. The e¡ect of antibodies to members of the Sp1 family of transcription factors on complexes
formed with probe D (376/354) and nuclear extract from Jurkat cells (J), ALL-2 T cells (A), normal resting T cells (R) or T cells
stimulated with PHA for 6 h (S6) is shown. The probes were incubated without (3) or with (+) the anti-Sp1, -Sp2, -Sp3, -Sp4 mono-
clonal antibodies, as indicated above each panel. Lane P is probe alone. The same pattern of supershift was seen with a larger probe,
probe B (3110/+5), except that the anti-Sp1 Ab caused a similar supershift in extracts from normal and leukemic T cells as seen in
Fig. 2.
Fig. 4. Analysis of Sp3 protein expression in normal and leukemic T cells. Expression of Sp3 was analyzed by Western blotting using
an anti-Sp3 antibody as detailed in Section 2. Panel A is a Western blot of whole nuclear protein extract from Jurkat cells (J), ALL-2
T cells (A), normal resting T cells (R) or T cells stimulated with PHA for 6 h (S6). Panel B is a Western blot of nuclear proteins
eluted from a probe D DNA-Sepharose a⁄nity column, and panel C shows the eluted proteins visualized with a silver-stained gel.
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By contrast, signi¢cant changes were observed when
site Sp1-3 was mutated (probe B:Sp1-3M, Fig. 5).
When site Sp1-3 was mutated, complex formation
was abolished in leukemic T cells (both the Jurkat
and the ALL cells), with the exception of complex IV
in the ALL extracts (Fig. 4). Furthermore, the Sp1
supershift was completely abolished for leukemic as
well as resting and PHA-activated T cells (Fig. 5)
when the Sp1-3 site was mutated. Complexes VI,
VII, and VIII were abolished in extracts from both
resting and stimulated T cells. Interestingly, however,
mutating the Sp1-3 site caused complex V, and to a
lesser extent complex IV, to become signi¢cantly
stronger in resting and activated T cell extracts
(Fig. 5). Together, the data suggest that other pro-
teins may bind better to the proximal region of the
promoter (represented by probe B) when binding of
factor(s) to the Sp1-3 site is abolished.
The above observations are in agreement with our
previous studies, which suggested that the nucleation
of complex formation in leukemic T cells is initiated
at the Sp1-3 site of the proximal MAT2A promoter
[27]. They also suggested that factors binding to the
normal Sp1-3 site e¡ectively compete with other fac-
tors for binding to sequences contained within this
region in normal T cells.
3.4. E¡ect of mutation of the Sp1 sites located
in the proximal MAT2A promoter on its
in vivo activity in normal and leukemic
T cells
The above data indicated that the e¡ect of mutat-
ing the Sp1-3 site located at position 369 in the
proximal MAT2A promoter on the in vitro promoter
activity is signi¢cantly di¡erent in normal and leuke-
mic T cells. This Sp1-3 site has been shown to be
essential for the in vivo activity of the MAT2A pro-
moter in leukemic T cells [27]. It was of interest,
therefore, to determine if this site is also important
for the in vivo promoter activity in normal resting
and activated T cells. The in vivo activity of a
MAT2A promoter construct with each of the three
Sp1 sites individually mutated was tested following
transfection into resting and activated T cells as
detailed in Section 2. As shown in Fig. 6, mutation
of the Sp1-1 or Sp1-2 site had little e¡ect on pro-
moter activity. By contrast, mutation of the Sp1-3
site reduced promoter activity by 85% (Fig. 6).
These results underscore the importance of the
Sp1-3 site in controlling the expression of the
MAT2A gene in both the normal and leukemic
T cells.
Fig. 5. E¡ect of mutating Sp1 sites in the proximal MAT2A promoter on patterns of protein^DNA interaction with extracts from
normal and leukemic T cells. Probe B:Sp1-1M, probe B:Sp1-2M, and probe B:Sp1-3M represent individually mutated Sp1-1, Sp1-2,
and Sp1-3 on probe B (3110/+5); probe B:WT is unmutated probe B. The probes were incubated with extracts from ALL-2 T cells
(A), resting T cells (R), or T cells stimulated with PHA for, 6 h (S6) without (3) and with (+) an Sp1 monoclonal antibody. Lane P
is probe alone. The complexes were analyzed by PAGE as detailed in Section 2 and Fig. 2.
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4. Discussion
The data presented in this study support the idea
that di¡erences in protein^DNA interactions may
contribute to signi¢cant di¡erences in MAT II regu-
lation in normal and malignant cells. Previous stud-
ies have shown that AdoMet pool size and fractional
turnover are quite di¡erent in normal and leukemic
human T cells, suggesting signi¢cant di¡erences in
the regulation of AdoMet synthesis in these cells
[22]. Further, the expression of MAT II K2 catalytic
subunit was found to be constitutively elevated in
leukemic T cells, while it is present at very low levels
in normal resting T lymphocytes. The data presented
here provide evidence for di¡erences in the pattern of
interaction between speci¢c functional regions of the
proximal MAT2A promoter and nuclear protein ex-
tracts from normal and leukemic T cells. We believe
that this ¢nding may shed light on the mechanism(s)
responsible for di¡erences in expression of MAT II
subunits, as well as for the di¡erential regulation of
AdoMet metabolism in normal and leukemic T cells.
The patterns of protein^DNA interaction found in
extracts of freshly explanted ALL cells and the estab-
lished human T cell leukemia line ^ Jurkat ^ were
very similar, indicating that, with respect to MAT2A
regulation, Jurkat is an appropriate representative of
human T cell leukemia. Unlike other T cell leukemia
lines, Jurkat can be activated with mitogenic signals
and stimulated to produce interleukin-2 (IL-2). Pre-
vious studies have shown that stimulation of Jurkat
by PHA induces IL-2 secretion but does not induce
further increase in MAT II K2 and L subunit expres-
sion, which are already expressed at constitutively
high levels in Jurkat, as well as in fresh leukemia
cells [16,22]. By contrast, the expression of the cata-
lytic K2/K2P subunits in normal resting T cells is very
low but can be signi¢cantly induced within hours of
PHA stimulation [16]. Maximal levels of the K2 sub-
unit mRNA in human T cells are reached within 4^8
h after PHA stimulation. It is of interest, therefore,
that the most signi¢cant changes in the pattern of
interaction between MAT2A promoter DNA and nu-
clear protein extracts were also found between 4 and
8 h of PHA stimulation (this study).
To delineate the molecular mechanism responsible
for di¡erences in K2 subunit expression in normal
resting, activated, and malignant T cells, we recently
cloned and characterized the human MAT2A pro-
moter and de¢ned a minimal promoter region be-
tween 358 and 387, relative to the transcription
start site, although signi¢cant enhancement in pro-
moter activity was contributed by sequences con-
tained within region 3110 to 3325 [27]. In EMSA,
extracts from Cos-1 and Jurkat leukemic cells were
shown to form three major high molecular weight
protein^DNA complexes (I, II, and III) with a probe
representing sequences from 3163 to +5 [27]. Smaller
probes covering this region demonstrated that there
is a pivotal Sp1 transcription factor recognition se-
quence within the minimal promoter at 369/363,
which we designated Sp1-3, that must be intact for
complex formation and for the in vivo promoter ac-
tivity in these cells [27]. However, the promoter se-
Fig. 6. E¡ect of mutation of Sp1 sites on MAT2A promoter in
vivo activity in resting and activated normal T cells. The three
Sp1 sites found within the pGL3-MAT2A (3110)-Luc reporter
construct were individually mutated at the underlined bases and
as detailed in Section 2. Reporter pGL3-MAT2A (3110)-Luc
constructs with and without Sp1 site mutations were transfected
into Jurkat cells (A), or resting and activated normal T cells
(B) and assayed for luciferase activity by the dual luciferase re-
porter assay system as detailed in Section 2. The data are pre-
sented as a percentage of the longest construct used, pGL3-
MAT2A (32374), which was set at 100% activity.
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quence from 3110 to +5 contains two additional Sp1
sites (Sp1-1 and Sp1-2 at positions 314/39 and 347/
339, respectively), and these must also be present
along with the Sp1-3 site to obtain supershifts with
an Sp1 antibody, suggesting cooperativity among the
three Sp1 sites [27].
In the current study, we show major di¡erences
between leukemic cells and normal T cells, both in
the resting stage and upon stimulation with PHA.
The Jurkat cells, as well as T lymphocytes from an
ALL patient, clearly have more protein factors that
participate in protein^DNA interactions than normal
resting and activated T cells when at least nucleotides
3110 to +5 of the MAT2A promoter are present
[27]. This ¢nding was evidenced by the formation
(with probes A^D) of large complexes I, II, and III
that were never seen in extracts from T cells, regard-
less of whether they had been stimulated by PHA or
not.
The pattern of complex formation with extracts
from resting and PHA-stimulated T cells was very
similar with few exceptions. Over a time course of
8 h of stimulating normal T cells with PHA, we
observed the transient appearance of a new complex
^ VI ^ at either 4 or 6 h post stimulation, but the
complex disappeared by 8 h after stimulation. The
kinetics of appearance of this complex overlaps the
timeframe of maximal K2 mRNA expression in
PHA-stimulated T cells [16]. Future studies will in-
vestigate whether there is a relationship between
these two events. Of interest is a complex formed
with probes C and D only and extracts from ALL
cells that migrates about the same distance as com-
plex VI. It remains to be determined whether this
complex contains the same protein factors responsi-
ble for complex VI in PHA-stimulated normal
T cells. Concomitant with the disappearance of com-
plex VI, we also observed the formation of a faint
but distinct complex ^ IX ^ in 8 h PHA-stimulated
normal T cells. This complex was seen only with
probes C and D but not A and B, suggesting that
protein factors that interact with DNA sequences
contained within the longer probes A and B may
be blocking the protein^DNA interactions necessary
for the formation of complex IX.
We previously observed that MAT2A promoter
nucleotides 3110 to +5 were required to obtain a
supershift with an Sp1 antibody in Cos-1 and Jurkat
cells [27]. The same phenomenon is observed here
with extracts from ALL T cells, normal resting
T cells, and PHA-stimulated T cells, indicating that
protein interaction involving the participation of
the transcription factor Sp1 with the region harbor-
ing all three Sp1 sites of the proximal MAT2A pro-
moter in all of these extracts is similar. By contrast,
supershift with anti-Sp2 and -Sp3 antibodies was
very di¡erent in normal and leukemic T cells. Both
antibodies induced signi¢cant supershift in extracts
from Jurkat and ALL leukemic T cells, whereas
they had no e¡ect on complexes formed with extracts
from resting or PHA-activated T cells. Although sev-
eral possibilities can be invoked, our data suggest
that low levels of expression of Sp2 and Sp3 in nor-
mal T cells may be responsible for the di¡erence in
the in vitro promoter activity between normal and
leukemic cells.
Mutation of sites Sp1-1 and Sp1-2 on probe B
(3110/+5) caused little perturbation with respect to
complex formation, except for complex V, which was
signi¢cantly diminished in normal resting T cell ex-
tracts. In addition, the supershift with Sp1 antibody
was unchanged when Sp1-1 and Sp1-2 sites were
mutated. On the other hand, mutation of site Sp1-3
changed the pattern of complex formation dramati-
cally in all cell extracts studied. Formation of com-
plexes I, II, III, and V in ALL cell extracts and
complexes VI, VII, and VIII in normal T cell extracts
were completely abolished. By contrast, complex IV
formation was largely una¡ected by mutation of site
Sp1-3, whereas complex V was signi¢cantly enhanced
in normal resting and PHA-activated T cells, suggest-
ing that protein binding to an intact Sp1-3 site pre-
vents other complex formation on proximal MAT2A
promoter. These factors are currently under investi-
gation.
These initial studies investigating the protein^
DNA complexes formed on the MAT2A promoter
provide evidence for signi¢cant di¡erences between
transformed and normal T lymphocytes, even when
stimulated with PHA. PHA stimulation by itself was
not su⁄cient to induce expression of proteins respon-
sible for the high molecular weight complexes seen in
the leukemic T cells. Together, the data show that
there are signi¢cant di¡erences in the regulation of
MAT2A in normal and malignant T cells. We believe
that unraveling these di¡erences will provide tools by
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which MAT2A expression can be manipulated in
cancerous cells and possibly halting their growth.
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